Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease (BLOCKCKD)

NCT03574363 PHASE2 COMPLETED Results posted

This is a Phase 2 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.

Details

Lead sponsor	KBP Biosciences
Phase	PHASE2
Status	COMPLETED
Enrolment	162
Start date	Wed Apr 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Aug 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Chronic Kidney Diseases
• Hypertension

Interventions

• KBP-5074 0.25 mg tablet
• KBP-5074 0.5 mg tablet

Countries

United States